Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1756-1760

  Mir, Olivier ^a,b   Alexandre, Jérôme ^a   Coriat, Romain ^a   Ropert, Stanislas ^a   Boudou Rouquette, Pascaline ^a   Bui, Thach ^b   Chapron, Jeanne ^b   Durand, Jean Philippe ^a   Dusser, Daniel ^b   Goldwasser, François ^a  

^a CERIA (Centre for Research on Angiogenesis Inhibitors)   (France)

^b Université Paris Descartes ^*  (France)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Hypertension; NSCLC; VEGF A

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; CLOPIDOGREL; DEXCHLORPHENIRAMINE MALEATE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTERY THROMBOSIS; ARTICLE; BLOOD PRESSURE MONITORING; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DYSPNEA; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RESPIRATORY TRACT DISEASE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84866734078     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9690-9     Document Type: Article

References (10)

1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550. doi:355/24/2542
2. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843-850
3. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19(3):851-856
4. Reidy DL, Chung KY, Timoney JP, Park VJ, Hollywood E, Sklarin NT, Muller RJ, Saltz LB (2007) Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 25(19):2691-2695. doi:25/19/2691
5. Coriat R, Mir O, Chaussade S, Goldwasser F (2010) Safety of 10min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients. Dig Liver Dis 43(3):248-249. doi:S1590-8658(10)00351-8
6. Dohn LH, Jensen BV, Larsen FO (2010) Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer. Acta Oncol 49(3):395-396. doi:10.3109/02841860903428184
7. Mahfoud T, Tanz R, Mesmoudi M, Khmamouche MR, Bazine A, Aassab R, Ismaili N, Boutayeb S, Ichou M, Errihani H (2010) Bevacizumab 5 or 7.5 mg/kg in Metastatic colorectal cancer can be infused safely over 10 minutes. J Gastrointest Cancer. doi:10.1007/s12029-010-9245-x
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342. doi:10.1056/NEJMoa032691
9. Durand JP, Madelaine I, Scotte F (2009) Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 96(10):951-960. doi:bdc.2009.0924
10. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II doseescalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30(5 Suppl 16):117-124. doi: S0093775403004469